Business
Zealand Pharma Announces Financial Results for the Full Year 2025
Company announcement – No. 1 / 2026 Zealand Pharma Announces Financial Results for the Full Year 2025 2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide, strong clinical progress, and organizational readiness, setting the stage for catalyst-rich and defining 2026 Entered a historic and transformative collaboration and license agreement with Roche to unlock the full potential of petrelintide as a future foundational therapy for weight management, aim
About this update from Zealand Pharma A/s
[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6gUCOEdJjLHihlE.VvDQtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Company announcement – No. 1 / 2026","length":35,"tagName":"p"},{"type":"text","content":"Zealand Pharma Announces Financial Results for the Full Year 2025","length":65,"tagName":"p"},{"type":"text","content":"2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide, strong clinical progress, and organizational readiness, setting the stage for catalyst-rich and defining 2026","length":208,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Entered a historic and transformative collaboration and license agreement with Roche to unlock the full potential of petrelintide as a future foundational therapy for weight management, aiming to establish the leading amylin-based franchise","length":240,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":240,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Positioned for the most catalyst-rich year in the company’s history, including Phase 2 petrelintide data from the ZUPREME program and Phase 3 survodutide data from the SYNCHRONIZETM obesity program","length":197,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":197,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Outlined ambitious Metabolic Frontier 2030 strategy to become a generational biotech and leader in obesity and metabolic health, targeting five launches, more than 10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030","length":255,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":255,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Announced plans to establish a research site in Boston to expand the pharmacological reach of our platform and integrate more than 25 years of proven peptide expertise with company-wide A...